Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 8 (2011), Issue 5 (May)

1. Polytherapy for the prophylaxis of chronic migraine: an Italian survey.
   Neurol Sci, 32: S185-8. [Abstract] [Full-text]
2. Priorities in Parkinson's disease research.
   Nat Rev Drug Discov, 10(5): 377-93. [Abstract] [Full-text]
3. Harnessing synthetic lethal interactions in anticancer drug discovery.
   Nat Rev Drug Discov, 10(5): 351-64. [Abstract] [Full-text]
4. Assessing the role of hydration in delirium at the end of life.
   Curr Opin Support Palliat Care, 5(2): 169-73. [Abstract] [Full-text]
5. A survey on the use of premedication prior to iodinated and gadolinium-based contrast material administration.
   J Am Coll Radiol, 8(5): 345-54. [Abstract] [Full-text]
6. Accelerated immunotherapy schedules and premedication.
   Immunol Allergy Clin North Am, 31(2): 251-63, ix. [Abstract] [Full-text]
7. Effects of N-vinylcaprolactam containing polyelectrolytes on hardness, fluoride release and water sorption of conventional glass ionomers.
   J Prosthet Dent, 105(5): 323-31. [Abstract] [Full-text]
8. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
   Acta Oncol, 50(4): 574-7. [Abstract] [Full-text]
9. Comparison of two tourniquets and determination of amikacin sulfate concentrations after metacarpophalangeal joint lavage performed simultaneously with intravenous regional limb perfusion in horses.
   Am J Vet Res, 72(5): 613-9. [Abstract] [Full-text]
10. Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride.
    J Neurosurg Pediatr, 7(5): 522-6. [Abstract] [Full-text]
11. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis.
    J Neurosurg Pediatr, 7(5): 468-74. [Abstract] [Full-text]
12. Benzodiazepines and adequacy of initial antidepressant treatment for depression.
    J Clin Psychopharmacol, 31(3): 360-4. [Abstract] [Full-text]
13. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression.
    J Clin Psychopharmacol, 31(3): 337-40. [Abstract] [Full-text]
14. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    J Clin Psychopharmacol, 31(3): 266-73. [Abstract] [Full-text]
15. What is a fluid challenge?
    Curr Opin Crit Care, 17(3): 290-5. [Abstract] [Full-text]
16. Seventy-five percent of National Football League teams use pregame hyperhydration with intravenous fluid.
    Clin J Sport Med, 21(3): 192-9. [Abstract] [Full-text]
17. Treatment with DAV for advanced-stage hemangiosarcoma in dogs.
    J Am Anim Hosp Assoc, 47(3): 170-8. [Abstract] [Full-text]
18. The effect of an interactive e-drug calculations package on nursing students' drug calculation ability and self-efficacy.
    Int J Med Inform, 80(6): 421-30. [Abstract] [Full-text]
19. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
    Bioorg Med Chem Lett, 21(10): 3088-91. [Abstract] [Full-text]
20. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization.
    J Biol Chem, 286(18): 16229-37. [Abstract] [Full-text]
21. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
    J Clin Oncol, 29(13): 1728-35. [Abstract] [Full-text]
22. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
    J Clin Oncol, 29(13): 1678-85. [Abstract] [Full-text]
23. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
    J Clin Oncol, 29(13): 1715-21. [Abstract] [Full-text]
24. Anti-malarial drug formulations and novel delivery systems: a review.
    Acta Trop, 118(2): 71-9. [Abstract] [Full-text]
25. Biofunctionalization of silicone polymers using poly(amidoamine) dendrimers and a mannose derivative for prolonged interference against pathogen colonization.
    Biomaterials, 32(19): 4336-46. [Abstract] [Full-text]
26. Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response.
    Biomaterials, 32(19): 4464-70. [Abstract] [Full-text]
27. TRP channels: emerging targets for respiratory disease.
    Pharmacol Ther, 130(3): 371-84. [Abstract] [Full-text]
28. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
    Cancer Res, 71(9): 3196-201. [Abstract] [Full-text]
29. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
    Eur Urol, 59(6): 912-8. [Abstract] [Full-text]
30. Micro-fabricated perforated polymer devices for long-term drug delivery.
    Biomed Microdevices, 13(3): 485-91. [Abstract] [Full-text]
31. Economic and outcomes-based analysis of the care of symptomatic varicose veins.
    J Surg Res, 168(1): 5-8. [Abstract] [Full-text]
32. Antimicrobial prophylaxis and infection surveillance in extracorporeal membrane oxygenation patients: a multi-institutional survey of practice patterns.
    ASAIO J, 57(3): 231-8. [Abstract] [Full-text]
33. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial.
    J Stroke Cerebrovasc Dis, 20(3): 177-82. [Abstract] [Full-text]
34. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries.
    Rofo, 183(5): 448-55. [Abstract] [Full-text]
35. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
    Haematologica, 96(5): 729-37. [Abstract] [Full-text]
36. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Acta Oncol, 50(4): 582-8. [Abstract] [Full-text]
37. Targeting the neurovascular unit for treatment of neurological disorders.
    Pharmacol Ther, 130(3): 239-47. [Abstract] [Full-text]
38. A systematic review and meta-analysis of the treatments of varicose veins.
    J Vasc Surg, 53(5): 49S-65S. [Abstract] [Full-text]
39. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.
    J Vasc Surg, 53(5): 2S-48S. [Abstract] [Full-text]
40. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
    Eur J Gastroenterol Hepatol, 23(6): 521-7. [Abstract] [Full-text]
41. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
    Clin Cancer Res, 17(9): 2852-62. [Abstract] [Full-text]
42. Late-life depression: evidence-based treatment and promising new directions for research and clinical practice.
    Psychiatr Clin North Am, 34(2): 335-55, vii-iii. [Abstract] [Full-text]
43. Hormonal management of the female-to-male transgender patient.
    J Midwifery Womens Health, 56(3): 293-302. [Abstract] [Full-text]
44. Adverse effects of topical photodynamic therapy.
    Photodermatol Photoimmunol Photomed, 27(3): 116-30. [Abstract] [Full-text]
45. Ophthalmia neonatorum: what kind of prophylaxis?
    J Matern Fetal Neonatal Med, 24(6): 769-73. [Abstract] [Full-text]
46. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    J Nucl Med, 52(5): 690-6. [Abstract] [Full-text]
47. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
    Lung Cancer, 72(3): 265-70. [Abstract] [Full-text]
48. Fluorenyl hexa-peri-hexabenzocoronene-dendritic oligothiophene hybrid materials: synthesis, photophysical properties, self-association behaviour and device performance.
    Chemistry, 17(20): 5549-60. [Abstract] [Full-text]
49. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol, 12(5): 460-8. [Abstract] [Full-text]
50. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
    Melanoma Res, 21(3): 223-7. [Abstract] [Full-text]
51. Chemotherapy for malignant pleural mesothelioma.
    Curr Treat Options Oncol, 12(2): 181-8. [Abstract] [Full-text]
52. A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC).
    Jpn J Clin Oncol, 41(5): 713-7. [Abstract] [Full-text]
53. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Melanoma Res, 21(3): 235-43. [Abstract] [Full-text]
54. Covalently linking poly(lactic-co-glycolic acid) nanoparticles to microbubbles before intravenous injection improves their ultrasound-targeted delivery to skeletal muscle.
    Small, 7(9): 1227-35. [Abstract] [Full-text]
55. Does dementia increase risk of thrombolysis?: a case-control study.
    Neurology, 76(18): 1575-80. [Abstract] [Full-text]
56. Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review.
    Lung Cancer, 72(3): 271-9. [Abstract] [Full-text]
57. Novel targeted therapies and vaccination strategies for mesothelioma.
    Curr Treat Options Oncol, 12(2): 149-62. [Abstract] [Full-text]
58. Protective effect of drug delivery systems against the enzymatic degradation of dermally applied DNAzyme.
    Int J Pharm, 410(1): 75-82. [Abstract] [Full-text]
59. Molecular modeling of gel nanoparticles with cyclosporine A for oral drug delivery.
    Int J Pharm, 410(1): 196-205. [Abstract] [Full-text]
60. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel.
    Int J Pharm, 410(1): 83-91. [Abstract] [Full-text]
61. Development of interferon alpha-2b microspheres with constant release.
    Int J Pharm, 410(1): 48-53. [Abstract] [Full-text]
62. α-Glucosyl hesperidin induced an improvement in the bioavailability of pranlukast hemihydrate using high-pressure homogenization.
    Int J Pharm, 410(1): 114-7. [Abstract] [Full-text]
63. Design of an expert system for the development and formulation of push-pull osmotic pump tablets containing poorly water-soluble drugs.
    Int J Pharm, 410(1): 41-7. [Abstract] [Full-text]
64. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
    Clin Exp Immunol, 164(3): 357-64. [Abstract] [Full-text]
65. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery.
    Int J Pharm, 410(1): 31-40. [Abstract] [Full-text]
66. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
    Curr Hematol Malig Rep, 6(2): 104-12. [Abstract] [Full-text]
67. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Clin Cancer Res, 17(9): 2799-806. [Abstract] [Full-text]
68. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
    Curr Hematol Malig Rep, 6(2): 136-44. [Abstract] [Full-text]
69. Ablative therapies for Barrett's esophagus.
    Curr Gastroenterol Rep, 13(3): 226-39. [Abstract] [Full-text]
70. Vinyl polymer-coated lorazepam particles for drug delivery to the airways.
    Int J Pharm, 410(1): 9-16. [Abstract] [Full-text]
71. Polymorphism of amino acid-based dendrons: from organogels to microcrystals.
    Chem Asian J, 6(5): 1163-70. [Abstract] [Full-text]
72. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
    Jpn J Clin Oncol, 41(5): 709-12. [Abstract] [Full-text]
73. Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
    Curr Hematol Malig Rep, 6(2): 113-9. [Abstract] [Full-text]
74. The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies.
    AAPS J, 13(2): 159-68. [Abstract] [Full-text]
75. Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
    Jpn J Clin Oncol, 41(5): 663-5. [Abstract] [Full-text]
76. New immunomodulatory drugs in myeloma.
    Curr Hematol Malig Rep, 6(2): 120-5. [Abstract] [Full-text]
77. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Jpn J Clin Oncol, 41(5): 617-23. [Abstract] [Full-text]
78. A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma.
    Jpn J Clin Oncol, 41(5): 630-6. [Abstract] [Full-text]
79. Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma.
    Clin Cancer Res, 17(9): 3039-47. [Abstract] [Full-text]
80. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.
    Clin Cancer Res, 17(9): 2628-37. [Abstract] [Full-text]
81. Microtubule-targeted agents: when mitochondria become essential to chemotherapy.
    Biochim Biophys Acta, 1807(6): 679-88. [Abstract] [Full-text]
82. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
    Eur J Cell Biol, 90(6): 527-35. [Abstract] [Full-text]
83. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Lung Cancer, 72(3): 327-32. [Abstract] [Full-text]
84. TS expression predicts postoperative recurrence in adenocarcinoma of the lung.
    Lung Cancer, 72(3): 360-4. [Abstract] [Full-text]
85. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
    Lung Cancer, 72(3): 378-83. [Abstract] [Full-text]
86. Approaches for targeting mitochondria in cancer therapy.
    Biochim Biophys Acta, 1807(6): 689-96. [Abstract] [Full-text]
87. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.
    PLoS One, 6(4): e18462. [Abstract] [Full-text]
88. Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART).
    Am J Trop Med Hyg, 84(5): 838-41. [Abstract] [Full-text]
89. Testosterone replacement therapy and cardiovascular risk factors modification.
    Aging Male, 14(2): 83-90. [Abstract] [Full-text]
90. Influence of time of day on propofol pharmacokinetics and pharmacodynamics in rabbits.
    Chronobiol Int, 28(4): 318-29. [Abstract] [Full-text]
91. Family strategies for achieving medication adherence in pediatric kidney transplantation.
    Nurs Res, 60(3): 190-6. [Abstract] [Full-text]
92. Encapsulation of phthalocyanine supramolecular stacks into virus-like particles.
    J Am Chem Soc, 133(18): 6878-81. [Abstract] [Full-text]
93. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics.
    Chem Commun (Camb), 47(20): 5699-701. [Abstract] [Full-text]
94. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma.
    J Vet Intern Med, 25(3): 511-7. [Abstract] [Full-text]
95. Controllable delivery of small-molecule compounds to targeted cells utilizing carbon nanotubes.
    J Am Chem Soc, 133(18): 6874-7. [Abstract] [Full-text]
96. Cancer burden in the HIV-infected population in the United States.
    J Natl Cancer Inst, 103(9): 753-62. [Abstract] [Full-text]
97. Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.
    J Neuroimmune Pharmacol, 6(2): 284-95. [Abstract] [Full-text]
98. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.
    Urology, 77(5): 1035-41. [Abstract] [Full-text]
99. Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons.
    AIDS, 25(8): 1113-8. [Abstract] [Full-text]
100. Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
     Urology, 77(5): 1172-6. [Abstract] [Full-text]
101. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
     Breast Cancer Res Treat, 127(2): 511-20. [Abstract] [Full-text]
102. Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin.
     Arch Pharm Res, 34(4): 583-92. [Abstract] [Full-text]
103. Rheological and mucoadhesive characterization of poly(vinylpyrrolidone) hydrogels designed for nasal mucosal drug delivery.
     Arch Pharm Res, 34(4): 573-82. [Abstract] [Full-text]
104. Biochemically altered human erythrocytes as a carrier for targeted delivery of primaquine: an in vitro study.
     Arch Pharm Res, 34(4): 563-71. [Abstract] [Full-text]
105. A combination of a microemulsion and a phospholipid complex for topical delivery of oxymatrine.
     Arch Pharm Res, 34(4): 551-62. [Abstract] [Full-text]
106. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
     Int J Gynecol Cancer, 21(4): 763-70. [Abstract] [Full-text]
107. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
     Int J Gynecol Cancer, 21(4): 685-9. [Abstract] [Full-text]
108. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis.
     Sci Transl Med, 3(81): 81ra35. [Abstract] [Full-text]
109. Nanomedicines--what are they?
     Drug Ther Bull, 49(5): 58-60; quiz iii-iv. [Abstract] [Full-text]
110. Folate-conjugated amphiphilic star-shaped block copolymers as targeted nanocarriers.
     J Biomed Mater Res A, 97(4): 498-508. [Abstract] [Full-text]
111. Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment.
     Acta Pharmacol Sin, 32(5): 552-64. [Abstract] [Full-text]
112. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.
     Acta Pharmacol Sin, 32(5): 545-51. [Abstract] [Full-text]
113. Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients.
     Ann Surg Oncol, 18(6): 1540-6. [Abstract] [Full-text]
114. Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.
     Cancer Prev Res (Phila), 4(5): 633-7. [Abstract] [Full-text]
115. HPMA based amphiphilic copolymers mediate central nervous effects of domperidone.
     Macromol Rapid Commun, 32(9): 712-7. [Abstract] [Full-text]
116. Facile synthesis of hierarchical conducting polymer nanotubes derived from nanofibers and their application for controlled drug release.
     Macromol Rapid Commun, 32(9): 729-35. [Abstract] [Full-text]
117. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
     Ann Surg Oncol, 18(6): 1575-81. [Abstract] [Full-text]
118. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
     Int J Gynecol Cancer, 21(4): 633-9. [Abstract] [Full-text]
119. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.
     Ann Surg Oncol, 18(6): 1710-6. [Abstract] [Full-text]
120. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
     Ann Surg Oncol, 18(6): 1766-74. [Abstract] [Full-text]
121. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
     Ann Surg Oncol, 18(6): 1582-9. [Abstract] [Full-text]
122. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
     Ann Surg Oncol, 18(6): 1644-50. [Abstract] [Full-text]
123. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
     Ann Surg Oncol, 18(6): 1590-8. [Abstract] [Full-text]
124. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study.
     Ann Surg Oncol, 18(6): 1560-7. [Abstract] [Full-text]
125. Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma.
     Ann Hematol, 90(6): 693-9. [Abstract] [Full-text]
126. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
     Ann Hematol, 90(6): 685-91. [Abstract] [Full-text]
127. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.
     Ann Hematol, 90(6): 675-84. [Abstract] [Full-text]
128. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
     AIDS Res Hum Retroviruses, 27(5): 461-8. [Abstract] [Full-text]
129. Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
     AIDS Res Hum Retroviruses, 27(5): 525-33. [Abstract] [Full-text]
130. Highly loaded, sustained-release microparticles of curcumin for chemoprevention.
     J Pharm Sci, 100(7): 2599-609. [Abstract] [Full-text]
131. Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma.
     Arch Pharm Res, 34(3): 407-17. [Abstract] [Full-text]
132. Pulsatile multiparticulate drug delivery system for metoprolol succinate.
     Arch Pharm Res, 34(3): 369-76. [Abstract] [Full-text]
133. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
     Int J Gynecol Cancer, 21(4): 673-7. [Abstract] [Full-text]
134. Deep vein thrombosis: rare cases of diagnoses in a pediatric emergency department.
     Pediatr Emerg Care, 27(5): 417-9. [Abstract] [Full-text]
135. Efficacy of limited cefuroxime prophylaxis in pediatric patients after cardiovascular surgery.
     Am J Health Syst Pharm, 68(10): 909-14. [Abstract] [Full-text]
136. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52.
     Expert Opin Biol Ther, 11(6): 821-4. [Abstract] [Full-text]
137. Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy.
     Clin Endocrinol (Oxf), 74(6): 687-93. [Abstract] [Full-text]
138. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
     Clin Endocrinol (Oxf), 74(6): 744-9. [Abstract] [Full-text]
139. Local delivery strategies in epilepsy: a focus on adenosine.
     Seizure, 20(5): 376-82. [Abstract] [Full-text]
140. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses.
     Nanoscale, 3(5): 2307-14. [Abstract] [Full-text]
141. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort.
     Cancer Epidemiol Biomarkers Prev, 20(5): 900-11. [Abstract] [Full-text]
142. Transport behavior of hairless mouse skin during constant current DC iontophoresis, part 2: iontophoresis of nonionic molecules with cotransport of polystyrene sulfonate oligomers.
     J Pharm Sci, 100(7): 2816-25. [Abstract] [Full-text]
143. Synthesis of hollow and mesoporous polycaprolactone nanocapsules.
     Nanoscale, 3(5): 2215-9. [Abstract] [Full-text]
144. Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.
     Breast J, 17(3): 230-8. [Abstract] [Full-text]
145. Coffees rich in chlorogenic acid or N-methylpyridinium induce chemopreventive phase II-enzymes via the Nrf2/ARE pathway in vitro and in vivo.
     Mol Nutr Food Res, 55(5): 798-802. [Abstract] [Full-text]
146. Conjugated polyelectrolyte-cisplatin complex nanoparticles for simultaneous in vivo imaging and drug tracking.
     Nanoscale, 3(5): 1997-2002. [Abstract] [Full-text]
147. Enzyme-catalyzed synthesis of a novel thermosensitive polyester with pendant ketoprofen.
     Macromol Biosci, 11(5): 595-9. [Abstract] [Full-text]
148. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
     Blood, 117(18): 4716-25. [Abstract] [Full-text]
149. Encapsulated enhanced green fluorescence protein in silica nanoparticle for cellular imaging.
     Nanoscale, 3(5): 1974-6. [Abstract] [Full-text]
150. Preparation of bleomycin A2-PLGA microspheres and related in vitro and in vivo studies.
     J Pharm Sci, 100(7): 2790-800. [Abstract] [Full-text]
151. Analysis of liquid crystalline nanoparticles by small angle X-ray diffraction: evaluation of drug and pharmaceutical additives influence on the internal structure.
     J Pharm Sci, 100(7): 2849-57. [Abstract] [Full-text]
152. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke.
     Atherosclerosis, 216(1): 205-11. [Abstract] [Full-text]
153. Evaluation of the effect of syringe surfaces on protein formulations.
     J Pharm Sci, 100(7): 2563-73. [Abstract] [Full-text]
154. Transdermal evaporation delivery system of praziquantel for schistosomiasis japonicum chemotherapy.
     J Pharm Sci, 100(7): 2769-77. [Abstract] [Full-text]
155. Long-term diabetic complications may be ameliorated by targeting Rho kinase.
     Diabetes Metab Res Rev, 27(4): 318-30. [Abstract] [Full-text]
156. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
     J Pharm Sci, 100(7): 2835-48. [Abstract] [Full-text]
157. Local drug delivery system: inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants.
     J Pharm Sci, 100(7): 2886-95. [Abstract] [Full-text]
158. Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance.
     J Pharm Sci, 100(7): 2693-702. [Abstract] [Full-text]
159. The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis.
     J Pharm Sci, 100(7): 2996-3009. [Abstract] [Full-text]
160. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
     J Pharm Sci, 100(7): 2665-84. [Abstract] [Full-text]
161. The effect of empiric antibiotic therapy on mortality in debilitated patients with dementia.
     Eur J Clin Microbiol Infect Dis, 30(6): 813-8. [Abstract] [Full-text]
162. Silica-maltose composites: obtaining drug carrier systems through tailored ultrastructural nanoparticles.
     J Pharm Sci, 100(7): 2826-34. [Abstract] [Full-text]
163. Sustained-release and swelling characteristics of xanthan gum/ethylcellulose-based injection moulded matrix tablets: in vitro and in vivo evaluation.
     J Pharm Sci, 100(7): 2858-70. [Abstract] [Full-text]
164. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies.
     Eur J Clin Microbiol Infect Dis, 30(6): 753-9. [Abstract] [Full-text]
165. Self-assembly strategy for the preparation of polymer-based nanoparticles for drug and gene delivery.
     Macromol Biosci, 11(5): 576-89. [Abstract] [Full-text]
166. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.
     Eur Radiol, 21(6): 1188-99. [Abstract] [Full-text]
167. Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.
     Drug Alcohol Depend, 115(1): 23-9. [Abstract] [Full-text]
168. Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.
     Stem Cells Dev, 20(5): 759-68. [Abstract] [Full-text]
169. The relation between the duty cycle and anesthetic effect in lidocaine iontophoresis using alternating current.
     Pain Pract, 11(3): 261-6. [Abstract] [Full-text]
170. A comparative subjective assessment study of PENNSAID® and Voltaren Gel®, two topical formulations of diclofenac sodium.
     Pain Pract, 11(3): 252-60. [Abstract] [Full-text]
171. Intraosseous line placement for antidote injection by first responders and receivers wearing personal protective equipment.
     Am J Emerg Med, 29(4): 373-81. [Abstract] [Full-text]
172. Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study.
     Dis Colon Rectum, 54(6): 729-35. [Abstract] [Full-text]
173. The contribution of labelling to safe medication administration in anaesthetic practice.
     Best Pract Res Clin Anaesthesiol, 25(2): 145-59. [Abstract] [Full-text]
174. Rapid endoscopic identification and destruction of degenerating Barrett's mucosal neoplasia.
     Surgeon, 9(3): 119-23. [Abstract] [Full-text]
175. Embolization during treatment of deep venous thrombosis: incidence, importance, and prevention.
     Tech Vasc Interv Radiol, 14(2): 58-64. [Abstract] [Full-text]
176. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
     BMC Cancer, 11: 140. [Abstract] [Full-text]
177. Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules.
     Micron, 42(6): 642-55. [Abstract] [Full-text]
178. Thiol-yne and thiol-ene "click" chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles.
     Biomacromolecules, 12(5): 1738-51. [Abstract] [Full-text]
179. Controlled release implants based on cast lipid blends.
     Eur J Pharm Sci, 43(1): 78-83. [Abstract] [Full-text]
180. Fluorescence investigation of a specific structure formed by aggregation of transglycosylated stevias: solubilizing effect of poorly water-soluble drugs.
     Eur J Pharm Sci, 43(1): 71-7. [Abstract] [Full-text]
181. Bioreducible micelles self-assembled from amphiphilic hyperbranched multiarm copolymer for glutathione-mediated intracellular drug delivery.
     Biomacromolecules, 12(5): 1567-77. [Abstract] [Full-text]
182. Multifunctional and degradable zwitterionic nanogels for targeted delivery, enhanced MR imaging, reduction-sensitive drug release, and renal clearance.
     Biomaterials, 32(20): 4604-8. [Abstract] [Full-text]
183. Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein.
     Eur J Pharm Sci, 43(1): 25-31. [Abstract] [Full-text]
184. Combinatorial discovery of peptide dendrimer enzyme models hydrolyzing isobutyryl fluorescein.
     ACS Comb Sci, 13(3): 310-20. [Abstract] [Full-text]
185. Drug target identification from protein dynamics using quantitative pathway analysis.
     J Proteome Res, 10(5): 2679-83. [Abstract] [Full-text]
186. Is prophylactic acyclovir treatment warranted for prevention of herpes simplex virus infections in facial burns? A review of the literature.
     J Burn Care Res, 32(3): 358-62. [Abstract] [Full-text]
187. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain.
     Free Radic Biol Med, 50(11): 1630-8. [Abstract] [Full-text]
188. Self-assembled chlorin e6 conjugated chondroitin sulfate nanodrug for photodynamic therapy.
     Biomacromolecules, 12(5): 1724-30. [Abstract] [Full-text]
189. Synthesis and characterization of dendron cross-linked PEG hydrogels as corneal adhesives.
     Biomacromolecules, 12(5): 1658-65. [Abstract] [Full-text]
190. Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy.
     Free Radic Biol Med, 50(11): 1546-55. [Abstract] [Full-text]
191. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.
     Free Radic Biol Med, 50(11): 1610-9. [Abstract] [Full-text]
192. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35.
     Trends Pharmacol Sci, 32(5): 317-25. [Abstract] [Full-text]
193. Vascular targeting of adipose tissue as an anti-obesity approach.
     Trends Pharmacol Sci, 32(5): 300-7. [Abstract] [Full-text]
194. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance.
     Eur J Pharm Biopharm, 78(2): 278-88. [Abstract] [Full-text]
195. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
     Nucleic Acids Res, 39(9): 3607-20. [Abstract] [Full-text]
196. Which therapy works better in choroid plexus carcinomas?
     J Neurooncol, 103(1): 155-62. [Abstract] [Full-text]
197. Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.
     J Neurooncol, 103(1): 87-102. [Abstract] [Full-text]
198. Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas.
     Pediatr Blood Cancer, 57(1): 84-8. [Abstract] [Full-text]
199. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
     Pediatr Blood Cancer, 57(1): 36-40. [Abstract] [Full-text]
200. Ultrasound-guided mesenteric lymph node iohexol injection for thoracic duct computed tomographic lymphography in cats.
     Vet Radiol Ultrasound, 52(3): 302-5. [Abstract] [Full-text]
201. Re-inventing intratumoral immunotherapy for melanoma.
     Immunotherapy, 3(5): 653-71. [Abstract] [Full-text]
202. Therapy for metastatic melanoma: an overview and update.
     Expert Rev Anticancer Ther, 11(5): 725-37. [Abstract] [Full-text]
203. Current clinical trials in castrate-resistant prostate cancer.
     Curr Urol Rep, 12(3): 173-9. [Abstract] [Full-text]
204. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
     Br J Haematol, 153(5): 599-611. [Abstract] [Full-text]
205. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
     Br J Haematol, 153(5): 582-8. [Abstract] [Full-text]
206. Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States.
     Am J Med Qual, 26(3): 174-80. [Abstract] [Full-text]
207. Radiation-sensitive diselenide block co-polymer micellar aggregates: toward the combination of radiotherapy and chemotherapy.
     Langmuir, 27(10): 5874-8. [Abstract] [Full-text]
208. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
     Clin Neurol Neurosurg, 113(5): 350-7. [Abstract] [Full-text]
209. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
     Pediatr Blood Cancer, 57(1): 47-55. [Abstract] [Full-text]
210. Thrombolysis for acute stroke in hemodialysis: international survey of expert opinion.
     Clin J Am Soc Nephrol, 6(5): 1089-93. [Abstract] [Full-text]
211. Fluid balance, diuretic use, and mortality in acute kidney injury.
     Clin J Am Soc Nephrol, 6(5): 966-73. [Abstract] [Full-text]
212. Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
     Pediatr Blood Cancer, 57(1): 69-75. [Abstract] [Full-text]
213. Nurse-delivered and doctor-delivered care in an attention deficit hyperactivity disorder follow-up clinic: a comparative study using propensity score matching.
     J Adv Nurs, 67(6): 1341-8. [Abstract] [Full-text]
214. Intravenous thrombolytic treatment in a patient with transient ischemic attack associated with mural carotid thrombi.
     Clin Neurol Neurosurg, 113(5): 416-8. [Abstract] [Full-text]
215. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
     Interact Cardiovasc Thorac Surg, 12(5): 812-7. [Abstract] [Full-text]
216. What is the best treatment for malignant pleural effusions?
     Interact Cardiovasc Thorac Surg, 12(5): 818-23. [Abstract] [Full-text]
217. Novel approach for talc pleurodesis by dedicated catheter through flexi-rigid thoracoscope under local anesthesia.
     Interact Cardiovasc Thorac Surg, 12(5): 667-70. [Abstract] [Full-text]
218. Apoptosis in glioma cells treated with PDT.
     Photomed Laser Surg, 29(5): 305-9. [Abstract] [Full-text]
219. 5-aminolevulinic acid-mediated photodynamic therapy on cervical condylomata acuminata.
     Photomed Laser Surg, 29(5): 339-43. [Abstract] [Full-text]
220. Lysyl oxidase: a potential target for cancer therapy.
     Inflammopharmacology, 19(3): 117-29. [Abstract] [Full-text]
221. Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer.
     J Thromb Thrombolysis, 31(4): 503-6. [Abstract] [Full-text]
222. Perioperative antibiotic process improvement reaps rewards.
     Am J Med Qual, 26(3): 185-92. [Abstract] [Full-text]
223. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
     JAMA, 305(18): 1873-81. [Abstract] [Full-text]
224. Evaluation of a novel non-penetrating electrode for use in DNA vaccination.
     PLoS One, 6(4): e19181. [Abstract] [Full-text]
225. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth.
     PLoS One, 6(5): e18758. [Abstract] [Full-text]
226. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
     JAMA, 305(18): 1873-81. [Abstract] [Full-text]
227. Can an electronic prescribing system detect doctors who are more likely to make a serious prescribing error?
     J R Soc Med, 104(5): 208-18. [Abstract] [Full-text]
228. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
     Int J Stroke, 6(3): 259-65. [Abstract] [Full-text]
229. Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery.
     Nano Lett, 11(5): 2096-103. [Abstract] [Full-text]
230. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
     Vaccine, 29(23): 3977-81. [Abstract] [Full-text]
231. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.
     Expert Opin Investig Drugs, 20(6): 779-93. [Abstract] [Full-text]
232. High-dose chemotherapy followed by autologous and allogeneic peripheral blood stem cell transplantation for recurrent disseminated trilateral retinoblastoma.
     Childs Nerv Syst, 27(6): 1019-24. [Abstract] [Full-text]
233. Decreasing trends of bacteraemia among HIV-infected Ugandan adults: incidence, aetiology, clinical outcomes and effect of antiretroviral therapy in a semi-urban setting (2000-2008).
     Trop Med Int Health, 16(6): 756-65. [Abstract] [Full-text]
234. Toll-like receptors as potential therapeutic targets in cardiac dysfunction.
     Expert Opin Ther Targets, 15(6): 753-65. [Abstract] [Full-text]
235. Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy.
     Expert Opin Ther Targets, 15(6): 767-80. [Abstract] [Full-text]
236. Therapeutic prospects for epigenetic modulation.
     Expert Opin Ther Targets, 15(6): 729-40. [Abstract] [Full-text]
237. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
     Leukemia, 25(5): 800-7. [Abstract] [Full-text]
238. People with AIDS (PWA) since highly active antiretroviral therapy, 1996.
     J Med Humanit, 32(2): 115-25. [Abstract] [Full-text]
239. Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation.
     Head Neck, 33(6): 808-16. [Abstract] [Full-text]
240. Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
241. Antibiotic prophylaxis for transrectal prostate biopsy.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
242. Thiolated chitosans: influence of various sulfhydryl ligands on permeation-enhancing and P-gp inhibitory properties.
     Drug Dev Ind Pharm, 37(6): 648-55. [Abstract] [Full-text]
243. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
     N Engl J Med, 364(19): 1817-25. [Abstract] [Full-text]
244. Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.
     J Pharmacokinet Pharmacodyn, 38(3): 369-83. [Abstract] [Full-text]
245. Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.
     Nat Rev Urol, 8(5): 282-5. [Abstract] [Full-text]
246. Epinephrine auto-injector use in adolescents at risk of anaphylaxis: a qualitative study in Scotland, UK.
     Clin Exp Allergy, 41(6): 869-77. [Abstract] [Full-text]
247. Intravenous thrombolysis in thromboembolic occlusion of the A1 segment of the left anterior cerebral artery only.
     Neurol Sci, 32(3): 511-2. [Abstract] [Full-text]
248. Novel drug delivery systems for glaucoma.
     Eye (Lond), 25(5): 578-86. [Abstract] [Full-text]
249. Hydrogen sulfide and erectile function: a novel therapeutic target.
     Nat Rev Urol, 8(5): 286-9. [Abstract] [Full-text]
250. Dissociation and charge transport in salts of dendronized ions in solvents of low polarity.
     J Phys Chem B, 115(19): 5801-6. [Abstract] [Full-text]
251. Evaluation of a new foam to increase skin hydration of the foot in type 2 diabetes: a pilot study.
     Int Wound J, 8(3): 297-300. [Abstract] [Full-text]
252. Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.
     Drug Dev Ind Pharm, 37(6): 673-84. [Abstract] [Full-text]
253. Protein micro and nanoencapsulation within glycol-chitosan/Ca²+/alginate matrix by spray drying.
     Drug Dev Ind Pharm, 37(6): 619-27. [Abstract] [Full-text]
254. Medication errors in the homes of children with chronic conditions.
     Arch Dis Child, 96(6): 581-6. [Abstract] [Full-text]
255. Early development evaluation of AZD8081: a substrate for the NK receptors.
     Drug Dev Ind Pharm, 37(6): 702-13. [Abstract] [Full-text]
256. Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
     Arch Gynecol Obstet, 283(6): 1363-8. [Abstract] [Full-text]
257. Differences in antibiotic prescribing in paediatric outpatients.
     Arch Dis Child, 96(6): 590-5. [Abstract] [Full-text]
258. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain.
     Drug Dev Ind Pharm, 37(6): 737-46. [Abstract] [Full-text]
259. Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques.
     Drug Dev Ind Pharm, 37(6): 727-36. [Abstract] [Full-text]
260. Air-assisted intranasal instillation enhances adenoviral delivery to the olfactory epithelium and respiratory tract.
     Gene Ther, 18(5): 432-6. [Abstract] [Full-text]
261. CQC outcome for medicines management: an outsider's inside view.
     Br Dent J, 210(9): 407-9. [Abstract] [Full-text]
262. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.
     Endocrinol Metab Clin North Am, 40(2): 419-32, ix. [Abstract] [Full-text]
263. The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy.
     J Am Coll Cardiol, 57(20): 2020-8. [Abstract] [Full-text]
264. Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.
     Br J Clin Pharmacol, 71(6): 929-35. [Abstract] [Full-text]
265. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group.
     Klin Padiatr, 223(3): 113-9. [Abstract] [Full-text]
266. Pediatric rapid fluid resuscitation.
     Curr Opin Pediatr, 23(3): 286-92. [Abstract] [Full-text]
267. Antibiotic prophylaxis and the prevention of surgical site infection.
     Curr Opin Pediatr, 23(3): 334-8. [Abstract] [Full-text]
268. Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009.
     Pharmacopsychiatry, 44(3): 114-8. [Abstract] [Full-text]
269. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain.
     Pain Med, 12(5): 755-60. [Abstract] [Full-text]
270. Application of fiber-optic attenuated total reflection-FT-IR methods for in situ characterization of protein delivery systems in real time.
     Anal Chem, 83(10): 3943-9. [Abstract] [Full-text]
271. Versatile electrochemiluminescence assays for cancer cells based on dendrimer/CdSe-ZnS-quantum dot nanoclusters.
     Anal Chem, 83(10): 3873-80. [Abstract] [Full-text]
272. Pigmentary complication of the peristomal skin in colorectal cancer patients under systemic chemotherapy using S-1: report of cases.
     J Wound Ostomy Continence Nurs, 38(3): 280-5. [Abstract] [Full-text]
273. Neurotoxicity of intrathecally administered fentanyl in a rat spinal model.
     Pain Med, 12(5): 717-25. [Abstract] [Full-text]
274. Epileptic seizure following IV tramadol in a patient with mental retardation and cerebellar ataxia.
     Pain Med, 12(5): 833-6. [Abstract] [Full-text]
275. The role of prophylactic antibiotics in laparoscopic cholecystectomy in preventing postoperative infection: a meta-analysis.
     J Laparoendosc Adv Surg Tech A, 21(4): 301-6. [Abstract] [Full-text]
276. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
     J Antimicrob Chemother, 66(6): 1351-3. [Abstract] [Full-text]
277. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections?
     J Antimicrob Chemother, 66(6): 1396-404. [Abstract] [Full-text]
278. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
     J Antimicrob Chemother, 66(6): 1346-50. [Abstract] [Full-text]
279. Incidence and characteristics of complications from epidural steroid injections.
     Pain Med, 12(5): 726-31. [Abstract] [Full-text]
280. Low-generation asymmetric dendrimers exhibit minimal toxicity and effectively complex DNA.
     J Pept Sci, 17(6): 470-8. [Abstract] [Full-text]
281. Electroporation therapy for T1 and T2 oral tongue cancer.
     Acta Otolaryngol, 131(6): 660-4. [Abstract] [Full-text]
282. A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer.
     J Cancer Res Clin Oncol, 137(6): 1005-13. [Abstract] [Full-text]
283. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
     J Cancer Res Clin Oncol, 137(6): 997-1003. [Abstract] [Full-text]
284. CT-guided needle aspiration of pneumothorax from a trigger point injection.
     Pain Med, 12(5): 837-41. [Abstract] [Full-text]
285. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.
     PLoS One, 6(5): e19617. [Abstract] [Full-text]
286. Interruption and defaulting of multidrug therapy against leprosy: population-based study in Brazil's Savannah Region.
     PLoS Negl Trop Dis, 5(5): e1031. [Abstract] [Full-text]
287. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations.
     Int J STD AIDS, 22(5): 256-62. [Abstract] [Full-text]
288. Treatment of brain metastases from germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 605-13, ix. [Abstract] [Full-text]
289. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 593-604, ix. [Abstract] [Full-text]
290. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 577-91, ix. [Abstract] [Full-text]
291. A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 557-76, viii -ix. [Abstract] [Full-text]
292. First-line chemotherapy of disseminated germ cell tumors.
     Hematol Oncol Clin North Am, 25(3): 543-56, viii. [Abstract] [Full-text]
293. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial.
     Am Heart J, 161(5): 848-54. [Abstract] [Full-text]
294. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
     Am Heart J, 161(5): 815-821.e6. [Abstract] [Full-text]
295. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
     Future Oncol, 7(5): 657-68. [Abstract] [Full-text]
296. Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.
     Future Oncol, 7(5): 649-56. [Abstract] [Full-text]
297. Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.
     Drugs, 71(7): 885-95. [Abstract] [Full-text]
298. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.
     Drugs, 71(7): 841-52. [Abstract] [Full-text]
299. Highly specific targeting and imaging of live cancer cells by using a peptide probe developed from rationally designed peptides.
     Chembiochem, 12(8): 1209-15. [Abstract] [Full-text]
300. Tunable supramolecular hydrogel for in situ encapsulation and sustained release of bioactive lysozyme.
     J Colloid Interface Sci, 359(2): 399-406. [Abstract] [Full-text]
301. Synthesis and immobilization of micro-scale drug particles in cellulosic films.
     Colloids Surf B Biointerfaces, 86(1): 181-8. [Abstract] [Full-text]
302. Lipid nanoparticles as vitamin matrix carriers in liquid food systems: On the role of high-pressure homogenisation, droplet size and adsorbed materials.
     Colloids Surf B Biointerfaces, 86(1): 119-24. [Abstract] [Full-text]
303. Au nanoparticles stabilised by PEGylated low generation PAMAM dendrimers: design, characterisation and properties.
     J Colloid Interface Sci, 359(2): 454-60. [Abstract] [Full-text]
304. Functionalization of biomolecules on nanoparticles: specialized for antibacterial applications.
     Appl Microbiol Biotechnol, 90(5): 1655-67. [Abstract] [Full-text]
305. Older adults' medication use 6 months before and after hip fracture: a population-based cohort study.
     J Am Geriatr Soc, 59(5): 863-8. [Abstract] [Full-text]
306. Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
     BMC Cancer, 11: 151. [Abstract] [Full-text]
307. Lipophilic rather than hydrophilic photosensitizers show strong adherence to standard cell culture microplates under cell-free conditions.
     J Photochem Photobiol B, 103(3): 222-9. [Abstract] [Full-text]
308. 1,4-Butanediol diglycidyl ether (BDE)-crosslinked PEI-g-imidazole nanoparticles as nucleic acid-carriers in vitro and in vivo.
     Mol Biosyst, 7(6): 2055-65. [Abstract] [Full-text]
309. Penetration of laser light through red blood cell ghosts.
     J Photochem Photobiol B, 103(3): 230-3. [Abstract] [Full-text]
310. Bacterial Ghosts as antigen and drug delivery system for ocular surface diseases: Effective internalization of Bacterial Ghosts by human conjunctival epithelial cells.
     J Biotechnol, 153(3): 167-75. [Abstract] [Full-text]
311. Modified PLA nano in situ gel: a potential ophthalmic drug delivery system.
     Colloids Surf B Biointerfaces, 86(1): 28-34. [Abstract] [Full-text]
312. Development and characterization of nanocapsules comprising dodecyltrimethylammonium chloride and κ-carrageenan.
     Colloids Surf B Biointerfaces, 86(1): 242-6. [Abstract] [Full-text]
313. Sexual risk taking among patients on antiretroviral therapy in an urban informal settlement in Kenya: a cross-sectional survey.
     J Int AIDS Soc, 14: 20. [Abstract] [Full-text]
314. The dexamethasone drug delivery system: indications and evidence.
     Adv Ther, 28(5): 351-66. [Abstract] [Full-text]
315. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.
     Int J Infect Dis, 15(6): e408-14. [Abstract] [Full-text]
316. Aerobic training abolishes ambulatory blood pressure increase induced by estrogen therapy: a double blind randomized clinical trial.
     Maturitas, 69(2): 189-94. [Abstract] [Full-text]
317. Release of hydrophobic anticancer drug from a newly designed self-assembling peptide.
     Mol Biosyst, 7(6): 2040-7. [Abstract] [Full-text]
318. Preparation and characterization of thermosensitive pluronic F127-b-poly(ɛ-caprolactone) mixed micelles.
     Colloids Surf B Biointerfaces, 86(1): 45-57. [Abstract] [Full-text]
319. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.
     Eur J Surg Oncol, 37(6): 543-8. [Abstract] [Full-text]
320. EMAS position statement: Managing menopausal women with a personal or family history of VTE.
     Maturitas, 69(2): 195-8. [Abstract] [Full-text]
321. Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide.
     Biomaterials, 32(21): 4914-24. [Abstract] [Full-text]
322. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy.
     Biomaterials, 32(21): 4976-86. [Abstract] [Full-text]
323. Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers.
     Biomaterials, 32(21): 4840-8. [Abstract] [Full-text]
324. Novel microbially triggered colon specific delivery system of 5-Fluorouracil: statistical optimization, in vitro, in vivo, cytotoxic and stability assessment.
     Int J Pharm, 411(1): 142-51. [Abstract] [Full-text]
325. Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells.
     Int J Pharm, 411(1): 136-41. [Abstract] [Full-text]
326. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels.
     Int J Pharm, 411(1): 128-35. [Abstract] [Full-text]
327. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
     Int J Pharm, 411(1): 178-87. [Abstract] [Full-text]
328. Liposome surface charge influence on skin penetration behaviour.
     Int J Pharm, 411(1): 223-31. [Abstract] [Full-text]
329. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy.
     Int J Pharm, 411(1): 106-12. [Abstract] [Full-text]
330. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
     Int J Pharm, 411(1): 78-85. [Abstract] [Full-text]
331. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.
     Int J Pharm, 411(1): 69-77. [Abstract] [Full-text]
332. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
     Expert Opin Investig Drugs, 20(5): 591-4. [Abstract] [Full-text]
333. Effect of surfactants and pH on naltrexone (NTX) permeation across buccal mucosa.
     Int J Pharm, 411(1): 92-7. [Abstract] [Full-text]
334. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
     Int J Pharm, 411(1): 206-14. [Abstract] [Full-text]
335. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.
     Cell Signal, 23(8): 1348-57. [Abstract] [Full-text]
336. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion.
     Int J Pharm, 411(1): 188-96. [Abstract] [Full-text]
337. Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.
     J Virol Methods, 174(1): 22-8. [Abstract] [Full-text]
338. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
     Eur J Surg Oncol, 37(6): 466-72. [Abstract] [Full-text]
339. Design and engineering of nanogels for cancer treatment.
     Drug Discov Today, 16(9): 457-63. [Abstract] [Full-text]
340. Isolation and evaluation of a polysaccharide from Prunus amygdalus as a carrier for transbuccosal delivery of Losartan potassium.
     Int J Biol Macromol, 48(5): 773-8. [Abstract] [Full-text]
341. Design and synthesis of a novel cationic thiolated polymer.
     Int J Pharm, 411(1): 10-7. [Abstract] [Full-text]
342. PAMAM G4 dendrimers affect the aggregation of α-synuclein.
     Int J Biol Macromol, 48(5): 742-6. [Abstract] [Full-text]
343. Synthesis and in vitro studies of biodegradable thiolated chitosan hydrogels for breast cancer therapy.
     Int J Biol Macromol, 48(5): 747-52. [Abstract] [Full-text]
344. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.
     Int J Pharm, 411(1): 1-9. [Abstract] [Full-text]
345. CT-guided epidural blood patching of directly observed or potential leak sites for the targeted treatment of spontaneous intracranial hypotension.
     AJNR Am J Neuroradiol, 32(5): 832-8. [Abstract] [Full-text]
346. A new simplified sonographic approach for pararadicular injections in the lumbar spine: a CT-controlled cadaver study.
     AJNR Am J Neuroradiol, 32(5): 828-31. [Abstract] [Full-text]
347. Genetic variability of pain perception and treatment--clinical pharmacological implications.
     Eur J Clin Pharmacol, 67(6): 541-51. [Abstract] [Full-text]
348. Multimodal imaging does not delay intravenous thrombolytic therapy in acute stroke.
     AJNR Am J Neuroradiol, 32(5): 864-8. [Abstract] [Full-text]
349. Sexual risk behaviors among HIV-infected South Indian couples in the HAART era: implications for reproductive health and HIV care delivery.
     AIDS Care, 23(6): 722-33. [Abstract] [Full-text]
350. ANCA vasculitis: time for a change in treatment paradigm? Not yet.
     Rheumatology (Oxford), 50(6): 1019-24. [Abstract] [Full-text]
351. Impact of a nutritional counseling program on prevention of HAART-related metabolic and morphologic abnormalities.
     AIDS Care, 23(6): 755-63. [Abstract] [Full-text]
352. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.
     Drug Alcohol Depend, 115(3): 237-9. [Abstract] [Full-text]
353. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
     Pituitary, 14(2): 148-56. [Abstract] [Full-text]
354. Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.
     Pathol Oncol Res, 17(2): 243-7. [Abstract] [Full-text]
355. Prophylactic antibiotic trends in transsphenoidal surgery for pituitary lesions.
     Pituitary, 14(2): 99-104. [Abstract] [Full-text]
356. Receptor-attached amphiphilic terpolymer for selective drug recognition in aqueous solutions.
     J Mol Recognit, 24(4): 678-86. [Abstract] [Full-text]
357. Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
     Onkologie, 34(5): 233-8. [Abstract] [Full-text]
358. Management of cutaneous metastases using electrochemotherapy.
     Acta Oncol, 50(5): 621-9. [Abstract] [Full-text]
359. Biomarkers in Alzheimer's disease drug development.
     Alzheimers Dement, 7(3): e13-44. [Abstract] [Full-text]
360. Online medication error graphic reports: a pilot in North Carolina nursing homes.
     J Patient Saf, 7(2): 92-8. [Abstract] [Full-text]
361. Predicting fluid responsiveness in mechanically ventilated children under general anaesthesia using dynamic parameters and transthoracic echocardiography.
     Br J Anaesth, 106(6): 856-64. [Abstract] [Full-text]
362. Size-controlled long-circulating PICsome as a ruler to measure critical cut-off disposition size into normal and tumor tissues.
     Chem Commun (Camb), 47(21): 6054-6. [Abstract] [Full-text]
363. Choline dendrimers as generic scaffolds for the non-covalent synthesis of multivalent protein assemblies.
     Chem Commun (Camb), 47(21): 5997-9. [Abstract] [Full-text]
364. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
     Clin Cancer Res, 17(10): 3219-32. [Abstract] [Full-text]
365. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
     Clin Cancer Res, 17(10): 3204-18. [Abstract] [Full-text]
366. Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.
     Neurobiol Dis, 43(1): 248-56. [Abstract] [Full-text]
367. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
     Clin Cancer Res, 17(10): 3388-97. [Abstract] [Full-text]
368. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.
     Cancer Res, 71(10): 3528-39. [Abstract] [Full-text]
369. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
     Clin Cancer Res, 17(10): 3259-71. [Abstract] [Full-text]
370. Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery.
     Ann Surg, 253(6): 1140-6. [Abstract] [Full-text]
371. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
     J Pharmacol Exp Ther, 337(3): 644-54. [Abstract] [Full-text]
372. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
     Clin Cancer Res, 17(10): 3490-9. [Abstract] [Full-text]
373. Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells.
     J Control Release, 151(2): 139-48. [Abstract] [Full-text]
374. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
     J Control Release, 151(2): 131-8. [Abstract] [Full-text]
375. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
     Clin Cancer Res, 17(10): 3233-47. [Abstract] [Full-text]
376. Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating.
     J Control Release, 151(2): 123-30. [Abstract] [Full-text]
377. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
     Clin Cancer Res, 17(10): 3398-407. [Abstract] [Full-text]
378. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.
     Clin Cancer Res, 17(10): 3248-58. [Abstract] [Full-text]
379. Dectin-1 targeting delivery of TNF-α antisense ODNs complexed with β-1,3-glucan protects mice from LPS-induced hepatitis.
     J Control Release, 151(2): 155-61. [Abstract] [Full-text]
380. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting.
     J Control Release, 151(2): 183-92. [Abstract] [Full-text]
381. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy.
     Arch Dermatol, 147(5): 590-6. [Abstract] [Full-text]
382. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation.
     J Control Release, 151(2): 176-82. [Abstract] [Full-text]
383. Exercise may reduce depression but not anxiety in self-referred cancer patients undergoing chemotherapy. Post-hoc analysis of data from the 'Body & Cancer' trial.
     Acta Oncol, 50(5): 660-9. [Abstract] [Full-text]
384. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.
     J Control Release, 151(2): 149-54. [Abstract] [Full-text]
385. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro.
     J Control Release, 151(2): 202-11. [Abstract] [Full-text]
386. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
     Clin Cancer Res, 17(10): 3431-42. [Abstract] [Full-text]
387. Pharmacomechanical thrombolysis for renal salvage after filter migration and renal vein thrombosis.
     J Vasc Surg, 53(5): 1391-3. [Abstract] [Full-text]
388. Gastrointestinal contents in fasted state and post-lipid ingestion: in vivo measurements and in vitro models for studying oral drug delivery.
     J Control Release, 151(2): 110-22. [Abstract] [Full-text]
389. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood.
     Metabolism, 60(6): 874-80. [Abstract] [Full-text]
390. Pulsed laser light forces cancer cells to absorb anticancer drugs--the role of water in nanomedicine.
     Artif Cells Blood Substit Immobil Biotechnol, 39(3): 169-73. [Abstract] [Full-text]
391. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.
     Asia Pac J Clin Oncol, 7: 34-40. [Abstract] [Full-text]
392. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
     Asia Pac J Clin Oncol, 7: 22-33. [Abstract] [Full-text]
393. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
     Asia Pac J Clin Oncol, 7: 13-21. [Abstract] [Full-text]
394. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
     Asia Pac J Clin Oncol, 7: 4-12. [Abstract] [Full-text]
395. A gold nanoshell with a silica inner shell synthesized using liposome templates for doxorubicin loading and near-infrared photothermal therapy.
     Int J Nanomedicine, 6: 807-13. [Abstract] [Full-text]
396. Consensus building for development of outpatient adverse drug event triggers.
     J Patient Saf, 7(2): 66-71. [Abstract] [Full-text]
397. Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
     J Comput Assist Tomogr, 35(3): 351-2. [Abstract] [Full-text]
398. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.
     Indian J Ophthalmol, 59(3): 242-6. [Abstract] [Full-text]
399. Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series.
     Asia Pac J Clin Oncol, 7(2): 174-9. [Abstract] [Full-text]
400. How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
     Asia Pac J Clin Oncol, 7(2): 129-35. [Abstract] [Full-text]
401. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.
     Asia Pac J Clin Oncol, 7(2): 106-13. [Abstract] [Full-text]
402. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.
     Helicobacter, 16(3): 225-8. [Abstract] [Full-text]
403. Effect of bile on the oral absorption of halofantrine in polyethylene glycol 400 and polysorbate 80 formulations dosed to bile duct cannulated rats.
     J Pharm Pharmacol, 63(6): 817-24. [Abstract] [Full-text]
404. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models.
     J Pharm Pharmacol, 63(6): 806-16. [Abstract] [Full-text]
405. Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.
     J Pharm Pharmacol, 63(6): 800-5. [Abstract] [Full-text]
406. A novel tri-layered buccal mucoadhesive patch for drug delivery: assessment of nicotine delivery.
     J Pharm Pharmacol, 63(6): 794-9. [Abstract] [Full-text]
407. In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs.
     J Pharm Pharmacol, 63(6): 780-5. [Abstract] [Full-text]
408. Effective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate.
     J Pharm Pharmacol, 63(6): 774-9. [Abstract] [Full-text]
409. Amphiphilic polylactic acid-hyperbranched polyglycerol nanoparticles as a controlled release system for poorly water-soluble drugs: physicochemical characterization.
     J Pharm Pharmacol, 63(6): 757-64. [Abstract] [Full-text]
410. Photosensitizer drug delivery via an optical fiber.
     J Am Chem Soc, 133(20): 7882-91. [Abstract] [Full-text]
411. Cationic poly(amidoamine) dendrimers as additives for capillary electroseparation and detection of proteins.
     Electrophoresis, 32(11): 1302-8. [Abstract] [Full-text]
412. Bispecific digoxigenin-binding antibodies for targeted payload delivery.
     Proc Natl Acad Sci U S A, 108(20): 8194-9. [Abstract] [Full-text]
413. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy.
     Nat Chem Biol, 7(6): 348-50. [Abstract] [Full-text]
414. An oral colon-targeting controlled release system based on resistant starch acetate: synthetization, characterization, and preparation of film-coating pellets.
     J Agric Food Chem, 59(10): 5738-45. [Abstract] [Full-text]
415. Biological performance of a novel biodegradable polyamidoamine hydrogel as guide for peripheral nerve regeneration.
     J Biomed Mater Res A, 98(1): 19-30. [Abstract] [Full-text]
416. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
     Int J Hematol, 93(5): 610-7. [Abstract] [Full-text]
417. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.
     Int J Hematol, 93(5): 602-9. [Abstract] [Full-text]
418. Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting.
     Bioconjug Chem, 22(5): 949-57. [Abstract] [Full-text]
419. Targeted albumin-based nanoparticles for delivery of amphipathic drugs.
     Bioconjug Chem, 22(5): 870-8. [Abstract] [Full-text]
420. Polyoxazoline: chemistry, properties, and applications in drug delivery.
     Bioconjug Chem, 22(5): 976-86. [Abstract] [Full-text]
421. Postoperative nosocomial endophthalmitis: is perioperative antibiotic prophylaxis advisable? A single centre's experience.
     J Hosp Infect, 78(2): 138-42. [Abstract] [Full-text]
422. Drug delivery through the skin barrier enhanced by treatment with tissue-tolerable plasma.
     Exp Dermatol, 20(6): 488-90. [Abstract] [Full-text]
423. Complications of loco-regional therapy in the liver-spectrum of imaging findings by CT and MRI.
     Emerg Radiol, 18(3): 249-56. [Abstract] [Full-text]
424. Does the length of the history influence the outcome of pneumatic reduction of intussusception in children?
     Pediatr Surg Int, 27(6): 587-9. [Abstract] [Full-text]
425. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.
     Pediatr Infect Dis J, 30(6): 535-7. [Abstract] [Full-text]
426. Accuracy of anterolateral versus posterolateral subtalar injection.
     Arch Orthop Trauma Surg, 131(6): 759-63. [Abstract] [Full-text]
427. Hospital systems for the detection and prevention of adverse drug events.
     Clin Pharmacol Ther, 89(6): 779-81. [Abstract] [Full-text]
428. Visual compatibility of common nebulizer medications with 7% sodium chloride solution.
     Am J Health Syst Pharm, 68(11): 1032-5. [Abstract] [Full-text]
429. Effect of bar-code-assisted medication administration on nurses' activities in an intensive care unit: a time-motion study.
     Am J Health Syst Pharm, 68(11): 1026-31. [Abstract] [Full-text]
430. Drug delivery systems in the treatment of African trypanosomiasis infections.
     Expert Opin Drug Deliv, 8(6): 735-47. [Abstract] [Full-text]
431. Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins.
     J Immunother, 34(5): 438-47. [Abstract] [Full-text]
432. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
     J Immunother, 34(5): 448-56. [Abstract] [Full-text]
433. Non-degradable polymer nanocomposites for drug delivery.
     Expert Opin Drug Deliv, 8(6): 765-78. [Abstract] [Full-text]
434. The redesigned follitropin α pen injector for infertility treatment.
     Expert Opin Drug Deliv, 8(6): 833-9. [Abstract] [Full-text]
435. Stents as a platform for drug delivery.
     Expert Opin Drug Deliv, 8(6): 813-31. [Abstract] [Full-text]
436. Long-lived, charge-shift states in heterometallic, porphyrin-based dendrimers formed via click chemistry.
     J Phys Chem A, 115(20): 5069-80. [Abstract] [Full-text]
437. Primary care physicians' adoption of new drugs is not associated with their clinical interests: a pharmacoepidemiologic study.
     Scand J Prim Health Care, 29(2): 117-21. [Abstract] [Full-text]
438. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria.
     Clin Pharmacol Ther, 89(6): 845-54. [Abstract] [Full-text]
439. Polysaccharides: a targeting strategy for colonic drug delivery.
     Expert Opin Drug Deliv, 8(6): 779-96. [Abstract] [Full-text]
440. Vaults engineered for hydrophobic drug delivery.
     Small, 7(10): 1432-9. [Abstract] [Full-text]
441. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
     J Clin Oncol, 29(15): 2060-5. [Abstract] [Full-text]
442. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
     J Clin Oncol, 29(15): 2040-5. [Abstract] [Full-text]
443. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
     J Clin Oncol, 29(15): 2011-9. [Abstract] [Full-text]
444. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
     J Natl Cancer Inst, 103(10): 817-25. [Abstract] [Full-text]
445. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
     J Clin Oncol, 29(15): 2032-9. [Abstract] [Full-text]
446. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs.
     Expert Opin Drug Deliv, 8(6): 749-63. [Abstract] [Full-text]
447. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
     J Clin Oncol, 29(15): 1997-2003. [Abstract] [Full-text]
448. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
     J Clin Oncol, 29(15): 2004-10. [Abstract] [Full-text]
449. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery.
     Expert Opin Drug Deliv, 8(6): 721-34. [Abstract] [Full-text]
450. Silk fibroin biomaterials for controlled release drug delivery.
     Expert Opin Drug Deliv, 8(6): 797-811. [Abstract] [Full-text]
451. Reproductive history and risk of colorectal cancer in postmenopausal women.
     J Natl Cancer Inst, 103(10): 826-34. [Abstract] [Full-text]
452. Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations.
     Expert Opin Drug Deliv, 8(6): 705-20. [Abstract] [Full-text]
453. Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.
     Antimicrob Agents Chemother, 55(6): 2499-505. [Abstract] [Full-text]
454. Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model--brief report.
     Arterioscler Thromb Vasc Biol, 31(6): 1357-9. [Abstract] [Full-text]
455. Multilayer coating of gold nanorods for combined stability and biocompatibility.
     Phys Chem Chem Phys, 13(21): 10028-35. [Abstract] [Full-text]
456. Carbohydrate nanoparticle-mediated colloidal assembly for prolonged efficacy of bacteriocin against food pathogen.
     Biotechnol Bioeng, 108(7): 1529-36. [Abstract] [Full-text]
457. Open- and closed-loop multiobjective optimal strategies for HIV therapy using NSGA-II.
     IEEE Trans Biomed Eng, 58(6): 1678-85. [Abstract] [Full-text]
458. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
     BJU Int, 107(11): 1722-32. [Abstract] [Full-text]
459. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
     J Neurooncol, 103(2): 371-9. [Abstract] [Full-text]
460. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
     Clin Infect Dis, 52(11): 1374-83. [Abstract] [Full-text]
461. Macular infarction after inadvertent intracameral cefuroxime.
     J Cataract Refract Surg, 37(6): 1168-9. [Abstract] [Full-text]
462. Dendronized polyaniline nanotubes for cardiac tissue engineering.
     Artif Organs, 35(5): 471-7. [Abstract] [Full-text]
463. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
     Expert Rev Clin Immunol, 7(3): 301-16. [Abstract] [Full-text]
464. Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal.
     Ocul Immunol Inflamm, 19(3): 214-5. [Abstract] [Full-text]
465. Drug-delivery strategies by using template-synthesized nanotubes.
     Chemistry, 17(23): 6296-302. [Abstract] [Full-text]
466. Hierarchical self-assembly of amphiphilic peptide dendrons: evolution of diverse chiral nanostructures through hydrogel formation over a wide pH range.
     Chemistry, 17(23): 6389-95. [Abstract] [Full-text]
467. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
     Bioorg Med Chem Lett, 21(11): 3335-41. [Abstract] [Full-text]
468. Macrocyclic chelator assembled RGD multimers for tumor targeting.
     Bioorg Med Chem Lett, 21(11): 3423-6. [Abstract] [Full-text]
469. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model.
     J Thorac Cardiovasc Surg, 141(6): 1522-8. [Abstract] [Full-text]
470. A new method using MRI to delineate areas of head and neck cancer targeted by intra-arterial infusion via a superficial temporal artery.
     Oral Oncol, 47(5): 387-90. [Abstract] [Full-text]
471. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.
     Breast Cancer Res Treat, 127(3): 689-96. [Abstract] [Full-text]
472. Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions.
     Cancer Sci, 102(6): 1216-22. [Abstract] [Full-text]
473. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.
     Blood, 117(20): 5391-402. [Abstract] [Full-text]
474. Foam sclerotherapy for spouting haemorrhage in patients with varicose veins.
     Eur J Vasc Endovasc Surg, 41(6): 856-8. [Abstract] [Full-text]
475. Changes in pulse pressure following fluid loading: a comparison between aortic root (non-invasive tonometry) and femoral artery (invasive recordings).
     Intensive Care Med, 37(6): 942-9. [Abstract] [Full-text]
476. Percutaneous sclerotherapy of massive macrocystic lymphatic malformations of the face and neck using fibrin glue with OK-432 and bleomycin.
     Int J Oral Maxillofac Surg, 40(6): 572-6. [Abstract] [Full-text]
477. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
     Blood, 117(20): 5314-20. [Abstract] [Full-text]
478. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.
     Diagn Microbiol Infect Dis, 70(2): 246-52. [Abstract] [Full-text]
479. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
     Cancer Sci, 102(6): 1171-5. [Abstract] [Full-text]
480. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy.
     Pain, 152(6): 1256-62. [Abstract] [Full-text]
481. District nurses' use for an assessment tool in their daily work with elderly patients' medication management.
     Scand J Public Health, 39(4): 354-60. [Abstract] [Full-text]
482. The complications of transforaminal lumbar epidural steroid injections.
     Spine (Phila Pa 1976), 36(13): E819-24. [Abstract] [Full-text]
483. Novel agents and future directions for refractory breast cancer.
     Semin Oncol, 38: S17-24. [Abstract] [Full-text]
484. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
     Leuk Lymphoma, 52: 79-81. [Abstract] [Full-text]
485. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population.
     PLoS One, 6(5): e19804. [Abstract] [Full-text]
486. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.
     J Clin Endocrinol Metab, 96(6): 1587-609. [Abstract] [Full-text]
487. Targeted gene therapy for the treatment of heart failure.
     Can J Cardiol, 27(3): 265-83. [Abstract] [Full-text]
488. Multiple intracerebral hemorrhages in an elderly patient after adding quetiapine to a stable warfarin regimen.
     Gen Hosp Psychiatry, 33(3): 302.e1-2. [Abstract] [Full-text]
489. Serotonin syndrome associated with polypharmacy in the elderly.
     Gen Hosp Psychiatry, 33(3): 301.e9-11. [Abstract] [Full-text]
490. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.
     Leuk Lymphoma, 52(6): 1055-65. [Abstract] [Full-text]
491. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience.
     Leuk Lymphoma, 52(6): 1041-8. [Abstract] [Full-text]
492. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
     Lancet, 377(9779): 1749-59. [Abstract] [Full-text]
493. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.
     Lancet Neurol, 10(6): 509-19. [Abstract] [Full-text]
494. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
     Biochem Biophys Res Commun, 408(4): 713-9. [Abstract] [Full-text]
495. Physicochemical characterization of drug-loaded rigid and elastic vesicles.
     Int J Pharm, 412(1): 142-7. [Abstract] [Full-text]
496. Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment.
     Fertil Steril, 95(7): 2324-9, 2329.e1-3. [Abstract] [Full-text]
497. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.
     Leuk Lymphoma, 52(6): 1030-40. [Abstract] [Full-text]
498. Vibrational spectra study of fluorescent dendrimers built from the cyclotriphosphazene core with terminal dansyl and carbamate groups.
     Spectrochim Acta A Mol Biomol Spectrosc, 79(3): 462-70. [Abstract] [Full-text]
499. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin.
     Int J Pharm, 412(1): 37-46. [Abstract] [Full-text]
500. Assessment of fluidity of different invasomes by electron spin resonance and differential scanning calorimetry.
     Int J Pharm, 412(1): 85-94. [Abstract] [Full-text]
501. Dissolution from solid lipid extrudates containing release modifiers.
     Int J Pharm, 412(1): 77-84. [Abstract] [Full-text]
502. Simultaneous controlled vitamin release from multiparticulates: theory and experiment.
     Int J Pharm, 412(1): 68-76. [Abstract] [Full-text]
503. The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery.
     Biomaterials, 32(22): 5269-78. [Abstract] [Full-text]
504. Redox-responsive nanocapsules for intracellular protein delivery.
     Biomaterials, 32(22): 5223-30. [Abstract] [Full-text]
505. Biodegradable and temperature-responsive polyurethanes for adriamycin delivery.
     Int J Pharm, 412(1): 52-8. [Abstract] [Full-text]
506. Preparation of microspheres containing low solubility drug compound by electrohydrodynamic spraying.
     Int J Pharm, 412(1): 59-67. [Abstract] [Full-text]
507. Effects of protein dose and delivery system on BMP-mediated bone regeneration.
     Biomaterials, 32(22): 5241-51. [Abstract] [Full-text]
508. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
     Int J Pharm, 412(1): 132-41. [Abstract] [Full-text]
509. The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy.
     Endocrinology, 152(6): 2256-65. [Abstract] [Full-text]
510. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
     Leuk Lymphoma, 52: 75-8. [Abstract] [Full-text]
511. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.
     Biomaterials, 32(22): 5123-33. [Abstract] [Full-text]
512. Facilitated nanoscale delivery of insulin across intestinal membrane models.
     Int J Pharm, 412(1): 123-31. [Abstract] [Full-text]
513. Experimental study on infusion devices containing polyvinyl chloride: to what extent are they di(2-ethylhexyl)phthalate-free?
     Int J Pharm, 412(1): 47-51. [Abstract] [Full-text]
514. Paraquat-loaded alginate/chitosan nanoparticles: preparation, characterization and soil sorption studies.
     J Hazard Mater, 190(1): 366-74. [Abstract] [Full-text]
515. Effect of local dual frequency sonication on drug distribution from polymeric nanomicelles.
     Ultrason Sonochem, 18(5): 1165-71. [Abstract] [Full-text]
516. Photochemical repair of vocal fold microflap defects.
     Laryngoscope, 121(6): 1244-51. [Abstract] [Full-text]
517. The use of lipid microtubes as a novel slow-release delivery system for laryngeal injection.
     Laryngoscope, 121(6): 1237-43. [Abstract] [Full-text]
518. Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy.
     Can J Cardiol, 27(3): 339-45. [Abstract] [Full-text]
519. Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART).
     Life Sci, 88(21): 909-16. [Abstract] [Full-text]
520. Current concepts and controversies in the management of early stage Hodgkin lymphoma.
     Leuk Lymphoma, 52(6): 962-71. [Abstract] [Full-text]
521. Investigation of the temperature stability of premarin intravenous using liquid chromatography-mass spectrometry.
     J Pharm Biomed Anal, 55(5): 1218-22. [Abstract] [Full-text]
522. Preventing asthma exacerbations: what are the targets?
     Pharmacol Ther, 131(1): 114-29. [Abstract] [Full-text]
523. Controlled delivery systems: from pharmaceuticals to cells and genes.
     Pharm Res, 28(6): 1241-58. [Abstract] [Full-text]
524. Strategies for bringing drug delivery tools into discovery.
     Int J Pharm, 412(1): 1-7. [Abstract] [Full-text]
525. Carcinosarcoma of the ovary: a case-control study.
     Gynecol Oncol, 121(3): 477-81. [Abstract] [Full-text]
526. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.
     Gynecol Oncol, 121(3): 542-5. [Abstract] [Full-text]
527. Chemo-immunotherapy for hairy cell leukemia.
     Leuk Lymphoma, 52: 72-4. [Abstract] [Full-text]
528. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
     Int J Pharm, 412(1): 106-14. [Abstract] [Full-text]
529. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.
     Steroids, 76(7): 636-52. [Abstract] [Full-text]
530. Clinical review: DHEA replacement for postmenopausal women.
     J Clin Endocrinol Metab, 96(6): 1642-53. [Abstract] [Full-text]
531. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency.
     J Clin Endocrinol Metab, 96(6): 1718-26. [Abstract] [Full-text]
532. Thrombolytic therapy in the treatment of right-sided prosthetic valve thrombosis in adults with congenital heart disease.
     Congenit Heart Dis, 6(3): 266-8. [Abstract] [Full-text]
533. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
     Gynecol Oncol, 121(3): 451-4. [Abstract] [Full-text]
534. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
     Cancer Immunol Immunother, 60(6): 793-808. [Abstract] [Full-text]
535. Pregnancy after lymphadenectomy and neoadjuvant chemotherapy followed by radical vaginal trachelectomy in FIGO stage IB1 cervical cancer.
     Fertil Steril, 95(7): 2431.e5-7. [Abstract] [Full-text]
536. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines.
     Leuk Lymphoma, 52(6): 994-1002. [Abstract] [Full-text]
537. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
     Leuk Lymphoma, 52(6): 986-93. [Abstract] [Full-text]
538. Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: a 10 years retrospective analysis.
     Eur Psychiatry, 26(4): 265-9. [Abstract] [Full-text]
539. Sonodynamic therapy using water-dispersed TiO2-polyethylene glycol compound on glioma cells: comparison of cytotoxic mechanism with photodynamic therapy.
     Ultrason Sonochem, 18(5): 1197-204. [Abstract] [Full-text]
540. Nano-fibrous tissue engineering scaffolds capable of growth factor delivery.
     Pharm Res, 28(6): 1273-81. [Abstract] [Full-text]
541. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
     Biol Blood Marrow Transplant, 17(6): 935-40. [Abstract] [Full-text]
542. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study.
     Dis Esophagus, 24(4): 258-64. [Abstract] [Full-text]
543. Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma.
     Dis Esophagus, 24(4): 251-7. [Abstract] [Full-text]
544. Hyperintense lesions in brain MRI after exposure to a mercuric chloride-containing skin whitening cream.
     Eur J Pediatr, 170(6): 747-50. [Abstract] [Full-text]
545. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV.
     Life Sci, 88(21): 940-7. [Abstract] [Full-text]
546. Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer.
     Jpn J Radiol, 29(4): 236-43. [Abstract] [Full-text]
547. Acute lithium intoxication: properly directing an index of suspicion.
     South Med J, 104(5): 371-2. [Abstract] [Full-text]
548. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
     J Infect Dis, 203(12): 1802-6. [Abstract] [Full-text]
549. Barriers for nurses to safe medication management in nursing homes.
     J Nurs Scholarsh, 43(2): 171-80. [Abstract] [Full-text]
550. Electrochemotherapy of cutaneous metastases of melanoma--a case series study and systematic review of the evidence.
     Dermatol Surg, 37(6): 816-24. [Abstract] [Full-text]
551. Outcomes of ultrasound-guided foam sclerotherapy for varicose veins of the lower extremities: a single center experience.
     Dermatol Surg, 37(6): 804-9. [Abstract] [Full-text]
552. Targeted synthesis of a 2D ordered porous organic framework for drug release.
     Chem Commun (Camb), 47(22): 6389-91. [Abstract] [Full-text]
553. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model.
     ACS Nano, 5(5): 4131-44. [Abstract] [Full-text]
554. Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery.
     ACS Nano, 5(5): 3839-48. [Abstract] [Full-text]
555. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis.
     Neurology, 76(21): 1838-40. [Abstract] [Full-text]
556. Triggered release of pharmacophores from [Ni(HAsO₃)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study.
     ACS Nano, 5(5): 3961-9. [Abstract] [Full-text]
557. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells.
     ACS Nano, 5(5): 3679-92. [Abstract] [Full-text]
558. Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes.
     ACS Nano, 5(5): 3493-505. [Abstract] [Full-text]
559. Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery.
     ACS Nano, 5(5): 3568-76. [Abstract] [Full-text]
560. Superbright multifluorescent core-shell mesoporous nanospheres as trackable transport carrier for drug.
     ACS Nano, 5(5): 3447-55. [Abstract] [Full-text]
561. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
     Mol Genet Metab, 103(2): 113-20. [Abstract] [Full-text]
562. Interactions of poly(amidoamine) dendrimers with human serum albumin: binding constants and mechanisms.
     ACS Nano, 5(5): 3456-68. [Abstract] [Full-text]
563. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
     Mol Genet Metab, 103(2): 121-7. [Abstract] [Full-text]
564. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
     Mol Genet Metab, 103(2): 107-12. [Abstract] [Full-text]
565. Combined Hurler and Sanfilippo syndrome in a sibling pair.
     Mol Genet Metab, 103(2): 135-7. [Abstract] [Full-text]
566. Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment.
     J Control Release, 151(3): 239-45. [Abstract] [Full-text]
567. Altering the drug release profiles of double-layered ternary-phase microparticles.
     J Control Release, 151(3): 229-38. [Abstract] [Full-text]
568. Sclerotherapy for vascular malformations in the oral and maxillofacial region: treatment and follow-up of 66 lesions.
     J Oral Maxillofac Surg, 69(6): e88-92. [Abstract] [Full-text]
569. Primary care physicians' perceptions of medication errors and error prevention in cooperation with community pharmacists.
     Res Social Adm Pharm, 7(2): 162-79. [Abstract] [Full-text]
570. Electro-gene transfer to skin using a noninvasive multielectrode array.
     J Control Release, 151(3): 256-62. [Abstract] [Full-text]
571. Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.
     J Control Release, 151(3): 295-301. [Abstract] [Full-text]
572. Menopausal hot flushes and vascular health.
     Ann Med, 43(4): 283-91. [Abstract] [Full-text]
573. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
     J Control Release, 151(3): 286-94. [Abstract] [Full-text]
574. Nanoscopic micelle delivery improves the photophysical properties and efficacy of photodynamic therapy of protoporphyrin IX.
     J Control Release, 151(3): 271-7. [Abstract] [Full-text]
575. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application.
     J Control Release, 151(3): 246-55. [Abstract] [Full-text]
576. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy.
     J Control Release, 151(3): 278-85. [Abstract] [Full-text]
577. Endosomal escape pathways for delivery of biologicals.
     J Control Release, 151(3): 220-8. [Abstract] [Full-text]
578. Mechanical and pharmacologic catheter-directed thrombolysis treatment of severe, symptomatic, bilateral deep vein thrombosis with congenital absence of the inferior vena cava.
     J Vasc Surg, 53(6): 1707-10. [Abstract] [Full-text]
579. Fully automated microinjection system for Xenopus laevis oocytes with integrated sorting and collection.
     J Lab Autom, 16(3): 186-96. [Abstract] [Full-text]
580. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
     Semin Ophthalmol, 26(3): 139-48. [Abstract] [Full-text]
581. Review of combination therapies for neovascular age-related macular degeneration.
     Semin Ophthalmol, 26(3): 114-20. [Abstract] [Full-text]
582. Intravitreal injection technique.
     Semin Ophthalmol, 26(3): 104-13. [Abstract] [Full-text]
583. Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery.
     Bioorg Med Chem, 19(11): 3341-6. [Abstract] [Full-text]
584. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
     Br J Cancer, 104(11): 1730-8. [Abstract] [Full-text]
585. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
     Proc Natl Acad Sci U S A, 108(21): 8785-90. [Abstract] [Full-text]
586. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
     Br J Cancer, 104(11): 1691-6. [Abstract] [Full-text]
587. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats.
     Eur J Pharm Sci, 43(3): 132-40. [Abstract] [Full-text]
588. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
     Eur J Pharm Sci, 43(3): 174-9. [Abstract] [Full-text]
589. Self-assembly of polyamines as a facile approach to fabricate permeability tunable polymeric shells for biomolecular encapsulation.
     ACS Appl Mater Interfaces, 3(5): 1665-74. [Abstract] [Full-text]
590. Adsorption of nonlamellar nanostructured liquid-crystalline particles to biorelevant surfaces for improved delivery of bioactive compounds.
     ACS Appl Mater Interfaces, 3(5): 1771-80. [Abstract] [Full-text]
591. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin.
     Vaccine, 29(25): 4218-24. [Abstract] [Full-text]
592. Endoscopic ultrasound-guided injection therapy for hepatobiliary disease.
     J Hepatobiliary Pancreat Sci, 18(3): 311-8. [Abstract] [Full-text]
593. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
     Antiviral Res, 90(3): 195-9. [Abstract] [Full-text]
594. Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project.
     J Am Med Dir Assoc, 12(5): 326-30. [Abstract] [Full-text]
595. Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients.
     J Am Med Dir Assoc, 12(5): 377-83. [Abstract] [Full-text]
596. Spontaneous intracranial hypotension in childhood: a case report and review of the literature.
     J Child Neurol, 26(6): 761-6. [Abstract] [Full-text]
597. Evaluation of a preoperative team briefing: a new communication routine results in improved clinical practice.
     BMJ Qual Saf, 20(6): 475-82. [Abstract] [Full-text]
598. Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever.
     Crit Care Med, 39(5): 993-9. [Abstract] [Full-text]
599. Thrombolytic therapy and visuoperceptual functions in right hemisphere infarct patients.
     J Neurol, 258(6): 1021-5. [Abstract] [Full-text]
600. Electronic notifications about drug substitutes can change physician prescription habits: a cross-sectional observational study.
     Med Decis Making, 31(3): 395-404. [Abstract] [Full-text]
601. Effects of chemotherapeutic agents for testicular cancer on rat spermatogonial stem/progenitor cells.
     J Androl, 32(4): 432-43. [Abstract] [Full-text]
602. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
     Am J Clin Oncol, 34(3): 309-13. [Abstract] [Full-text]
603. Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy in breast cancer.
     Am J Clin Oncol, 34(3): 238-44. [Abstract] [Full-text]
604. Menopausal hormone therapy: what we know now.
     Am J Nurs, 111(6): 38-47; quiz 48-9. [Abstract] [Full-text]
605. Abiraterone and increased survival in metastatic prostate cancer.
     N Engl J Med, 364(21): 1995-2005. [Abstract] [Full-text]
606. Off-label use of medical products.
     Prehosp Emerg Care, 15(3): 419. [Abstract] [Full-text]
607. Thrombolysis treatment for acute stroke: issues of efficacy and utilization in women.
     Womens Health (Lond Engl), 7(3): 383-90. [Abstract] [Full-text]
608. Hormone therapy administration in postmenopausal women and risk of stroke.
     Womens Health (Lond Engl), 7(3): 355-61. [Abstract] [Full-text]
609. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
     Nanotechnology, 22(27): 275102. [Abstract] [Full-text]
610. Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.
     Diabetes Technol Ther, 13(6): 601-6. [Abstract] [Full-text]
611. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients.
     Diabetes Technol Ther, 13(6): 657-60. [Abstract] [Full-text]
612. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
     Diabetes Technol Ther, 13(6): 607-14. [Abstract] [Full-text]
613. Autoimmune polyglandular syndrome type 2 induced by treatment with interferon alpha.
     Am J Med Sci, 341(6): 504-7. [Abstract] [Full-text]
614. What provokes experienced COPD clinical practitioners in the UK to initiate or change medication? A consensus study.
     Prim Care Respir J, 20(2): 155-60, 2 p following 160. [Abstract] [Full-text]
615. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis.
     Anesth Analg, 112(6): 1411-21. [Abstract] [Full-text]
616. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
     Cancer Chemother Pharmacol, 67(6): 1455-61. [Abstract] [Full-text]
617. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.
     Ann Oncol, 22(6): 1382-91. [Abstract] [Full-text]
618. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
     Ann Oncol, 22(6): 1266-72. [Abstract] [Full-text]
619. The efficacy of combination antiretroviral therapy in HIV type 1-infected patients treated in Curaçao compared with Antillean, Surinam, and Dutch HIV type 1-infected patients treated in The Netherlands.
     AIDS Res Hum Retroviruses, 27(6): 605-12. [Abstract] [Full-text]
620. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
     Ann Oncol, 22(6): 1358-66. [Abstract] [Full-text]
621. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
     Ann Oncol, 22(6): 1308-17. [Abstract] [Full-text]
622. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
     Ann Oncol, 22(6): 1250-8. [Abstract] [Full-text]
623. Short communication: enhancement of immunogenicity of replication-defective adenovirus-based human immunodeficiency virus vaccines in rhesus monkeys.
     AIDS Res Hum Retroviruses, 27(6): 681-6. [Abstract] [Full-text]
624. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
     AIDS Res Hum Retroviruses, 27(6): 597-603. [Abstract] [Full-text]
625. Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.
     AIDS Res Hum Retroviruses, 27(6): 659-67. [Abstract] [Full-text]
626. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
     Cancer Chemother Pharmacol, 67(6): 1429-34. [Abstract] [Full-text]
627. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
     Cancer Chemother Pharmacol, 67(6): 1435-43. [Abstract] [Full-text]
628. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
     Cancer Chemother Pharmacol, 67(6): 1423-8. [Abstract] [Full-text]
629. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
     Cancer Chemother Pharmacol, 67(6): 1363-8. [Abstract] [Full-text]
630. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
     Cancer Chemother Pharmacol, 67(6): 1323-31. [Abstract] [Full-text]
631. Sclerotherapy for lymphatic malformations in children: a scoping review.
     J Pediatr Surg, 46(5): 912-22. [Abstract] [Full-text]
632. Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
     Br J Dermatol, 164(6): 1362-8. [Abstract] [Full-text]
633. Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target.
     Toxicol Appl Pharmacol, 253(3): 270-81. [Abstract] [Full-text]
634. Silica nanocapsules of fluorescent conjugated polymers and superparamagnetic nanocrystals for dual-mode cellular imaging.
     Chemistry, 17(24): 6696-706. [Abstract] [Full-text]
635. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
     Br J Haematol, 153(6): 729-40. [Abstract] [Full-text]
636. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
     Respir Res, 12: 54. [Abstract] [Full-text]
637. Update: treatment of cutaneous viral warts in children.
     Pediatr Dermatol, 28(3): 217-29. [Abstract] [Full-text]
638. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.
     J Vasc Interv Radiol, 22(6): 780-6. [Abstract] [Full-text]
639. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
     J Hematol Oncol, 4: 18. [Abstract] [Full-text]
640. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
     Eur J Cancer, 47(9): 1299-304. [Abstract] [Full-text]
641. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy.
     Proteomics Clin Appl, 5(5): 354-66. [Abstract] [Full-text]
642. Acute iliofemoral venous thrombosis in patients with atresia of the inferior vena cava can be treated successfully with catheter-directed thrombolysis.
     J Vasc Interv Radiol, 22(6): 801-5. [Abstract] [Full-text]
643. Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
     Eur J Cancer, 47(9): 1336-42. [Abstract] [Full-text]
644. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
     Am J Ophthalmol, 151(6): 953-960.e2. [Abstract] [Full-text]
645. Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma.
     Blood, 117(21): 5616-9. [Abstract] [Full-text]
646. Management of chylothorax in adults: when is surgery indicated?
     Thorac Cardiovasc Surg, 59(4): 243-6. [Abstract] [Full-text]
647. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection.
     Blood, 117(21): 5582-90. [Abstract] [Full-text]
648. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
     Eur J Cancer, 47(9): 1312-8. [Abstract] [Full-text]
649. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model.
     Int J Cancer, 129(3): 648-58. [Abstract] [Full-text]
650. Frameless stereotactic aspiration and subsequent fibrinolytic therapy for the treatment of spontaneous intracerebral haemorrhage.
     Br J Neurosurg, 25(3): 369-75. [Abstract] [Full-text]
651. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
     J Thorac Oncol, 6(6): 1128-31. [Abstract] [Full-text]
652. Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
     J Thorac Oncol, 6(5): 951-3. [Abstract] [Full-text]
653. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
     J Thorac Oncol, 6(5): 942-6. [Abstract] [Full-text]
654. Infective endocarditis: the European viewpoint.
     Curr Probl Cardiol, 36(5): 175-222. [Abstract] [Full-text]
655. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
     Lancet, 377(9780): 1846-54. [Abstract] [Full-text]
656. Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin.
     J Chin Med Assoc, 74(6): 272-4. [Abstract] [Full-text]
657. Late diagnosis of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: role of socio-behavioral factors and medical encounters.
     J Formos Med Assoc, 110(5): 306-15. [Abstract] [Full-text]
658. Testosterone and prostate cancer: what are the risks for middle-aged men?
     Urol Clin North Am, 38(2): 119-24. [Abstract] [Full-text]
659. Perioperative intra- and extravascular volume in liver transplant recipients.
     Transplant Proc, 43(4): 1098-102. [Abstract] [Full-text]
660. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
     Ann Thorac Surg, 91(6): 1738-45. [Abstract] [Full-text]
661. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
     Am J Cardiovasc Drugs, 11(3): 145-52. [Abstract] [Full-text]
662. Could different hydration protocols affect the quality of 18F-FDG PET/CT images?
     J Nucl Med Technol, 39(2): 77-82. [Abstract] [Full-text]
663. Evaluating the medication process in the context of CPOE use: the significance of working around the system.
     Int J Med Inform, 80(7): 490-506. [Abstract] [Full-text]
664. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux.
     Biomaterials, 32(23): 5524-33. [Abstract] [Full-text]
665. Cell signaling molecules as drug targets in lung cancer: an overview.
     Curr Opin Pulm Med, 17(4): 286-91. [Abstract] [Full-text]
666. Folate-decorated nanogels for targeted therapy of ovarian cancer.
     Biomaterials, 32(23): 5417-26. [Abstract] [Full-text]
667. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
     J Thorac Oncol, 6(6): 1121-7. [Abstract] [Full-text]
668. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
     J Thorac Oncol, 6(6): 1098-103. [Abstract] [Full-text]
669. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
     J Thorac Oncol, 6(6): 1104-9. [Abstract] [Full-text]
670. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
     J Thorac Oncol, 6(6): 1079-86. [Abstract] [Full-text]
671. Thermoresponsive nanostructured polycarbonate block copolymers as biodegradable therapeutic delivery carriers.
     Biomaterials, 32(23): 5505-14. [Abstract] [Full-text]
672. An injectable calcium phosphate cement for the local delivery of paclitaxel to bone.
     Biomaterials, 32(23): 5411-6. [Abstract] [Full-text]
673. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
     Gynecol Oncol, 122(1): 183-9. [Abstract] [Full-text]
674. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
     Gynecol Oncol, 122(1): 89-94. [Abstract] [Full-text]
675. Frequency of increased blood pressure levels during systemic thrombolysis and risk of intracerebral hemorrhage.
     Stroke, 42(6): 1702-6. [Abstract] [Full-text]
676. Transfer delay is a major factor limiting the use of intra-arterial treatment in acute ischemic stroke.
     Stroke, 42(6): 1626-30. [Abstract] [Full-text]
677. The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy.
     Jpn J Clin Oncol, 41(6): 739-46. [Abstract] [Full-text]
678. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
     Gynecol Oncol, 122(1): 116-20. [Abstract] [Full-text]
679. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.
     Gynecol Oncol, 122(1): 9-13. [Abstract] [Full-text]
680. Changes in pulmonary artery pressures during ethanol sclerotherapy for arteriovenous malformations: identifying the most vulnerable period.
     Clin Radiol, 66(7): 639-44. [Abstract] [Full-text]
681. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
     J Thorac Oncol, 6(6): 1117-20. [Abstract] [Full-text]
682. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.
     J Thorac Oncol, 6(6): 1092-7. [Abstract] [Full-text]
683. Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke.
     Stroke, 42(6): 1638-43. [Abstract] [Full-text]
684. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
     J Clin Oncol, 29(16): 2171-7. [Abstract] [Full-text]
685. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
     J Clin Oncol, 29(16): 2215-22. [Abstract] [Full-text]
686. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
     Jpn J Clin Oncol, 41(6): 747-51. [Abstract] [Full-text]
687. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series.
     Stroke, 42(6): 1771-4. [Abstract] [Full-text]
688. A feasibility study to evaluate a novel drug delivery technique through nasal/sinus mucosa using a biodegradable polymer in a guinea pig model.
     Otolaryngol Head Neck Surg, 144(6): 978-81. [Abstract] [Full-text]
689. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
     J Clin Oncol, 29(16): 2191-8. [Abstract] [Full-text]
690. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
     Cancer Lett, 307(1): 47-52. [Abstract] [Full-text]
691. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
     Jpn J Clin Oncol, 41(6): 770-5. [Abstract] [Full-text]
692. A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients.
     Jpn J Clin Oncol, 41(6): 764-9. [Abstract] [Full-text]
693. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
     J Clin Oncol, 29(16): 2178-84. [Abstract] [Full-text]
694. Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells.
     Acta Biomater, 7(7): 2873-82. [Abstract] [Full-text]
695. The macro domain protein family: structure, functions, and their potential therapeutic implications.
     Mutat Res, 727(3): 86-103. [Abstract] [Full-text]
696. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
     J Thorac Oncol, 6(6): 1110-6. [Abstract] [Full-text]
697. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
     J Thorac Oncol, 6(6): 1087-91. [Abstract] [Full-text]
698. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
     J Thorac Oncol, 6(5): 927-33. [Abstract] [Full-text]
699. Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience.
     Jpn J Clin Oncol, 41(6): 776-82. [Abstract] [Full-text]
700. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.
     Int J Drug Policy, 22(3): 210-8. [Abstract] [Full-text]
701. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
     J Thorac Oncol, 6(5): 934-41. [Abstract] [Full-text]
702. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
     J Thorac Oncol, 6(5): 852-63. [Abstract] [Full-text]
703. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo.
     FASEB J, 25(6): 1865-73. [Abstract] [Full-text]
704. Challenges in posthospital care: nurses as coaches for medication management.
     J Nurs Care Qual, 26(3): 243-51. [Abstract] [Full-text]
705. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.
     Nanomedicine, 7(3): 324-32. [Abstract] [Full-text]
706. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison.
     Nanomedicine, 7(3): 295-304. [Abstract] [Full-text]
707. Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation.
     Nanomedicine, 7(3): 284-94. [Abstract] [Full-text]
708. Copper complex of a pyridine-modified poly(amidoamine) dendrimer as a chemical nuclease: synthetic and catalytic study.
     Nanomedicine, 7(3): 273-6. [Abstract] [Full-text]
709. Systemic fibrinolysis through intraosseous vascular access in ST-segment elevation myocardial infarction.
     Ann Emerg Med, 57(6): 572-4. [Abstract] [Full-text]
710. Luminescence targeting and imaging using a nanoscale generation 3 dendrimer in an in vivo colorectal metastatic rat model.
     Nanomedicine, 7(3): 249-58. [Abstract] [Full-text]
711. Predictors of long-term anti-retroviral therapy effectiveness among Brazilian HIV-1-infected children in a hybrid scenario: what really matters?
     J Trop Pediatr, 57(3): 197-203. [Abstract] [Full-text]
712. Mechanical intestinal cleansing and antibiotic prophylaxis for preventing bacterial translocation during the Pringle maneuver in rabbits.
     Surg Today, 41(6): 824-8. [Abstract] [Full-text]
713. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
     PLoS One, 6(5): e17956. [Abstract] [Full-text]
714. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
     Lancet Oncol, 12(6): 527-39. [Abstract] [Full-text]
715. pH-induced changes in the fabrication of multilayers of poly(acrylic acid) and chitosan: fabrication, properties, and tests as a drug storage and delivery system.
     Langmuir, 27(11): 6836-45. [Abstract] [Full-text]
716. Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging.
     Langmuir, 27(11): 6971-6. [Abstract] [Full-text]
717. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging.
     Chem Asian J, 6(6): 1381-9. [Abstract] [Full-text]
718. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse.
     Neuropharmacology, 61(1): 283-92. [Abstract] [Full-text]
719. Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery.
     Small, 7(11): 1569-78. [Abstract] [Full-text]
720. Influence of biological media on the structure and behavior of ferrocene-containing cationic lipid/DNA complexes used for DNA delivery.
     Langmuir, 27(11): 6615-21. [Abstract] [Full-text]
721. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status.
     Lung, 189(3): 199-206. [Abstract] [Full-text]
722. Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [(3)H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain.
     Neuropharmacology, 61(1): 161-71. [Abstract] [Full-text]
723. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
     Lung, 189(3): 193-8. [Abstract] [Full-text]
724. Molecular determinants for the subtype specificity of μ-conotoxin SIIIA targeting neuronal voltage-gated sodium channels.
     Neuropharmacology, 61(1): 105-11. [Abstract] [Full-text]
725. Errors associated with the concentration of epinephrine in endonasal surgery.
     Eur Arch Otorhinolaryngol, 268(7): 1009-11. [Abstract] [Full-text]
726. Antibiotic administration longer than eight hours after triage and mortality of community-acquired pneumonia in patients with diabetes mellitus.
     Eur J Clin Microbiol Infect Dis, 30(7): 881-6. [Abstract] [Full-text]
727. Multiple substance use among heroin-dependent patients before and during attendance at methadone maintenance treatment program, Yunnan, China.
     Drug Alcohol Depend, 116(1): 246-9. [Abstract] [Full-text]
728. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP).
     Eur J Clin Microbiol Infect Dis, 30(7): 853-5. [Abstract] [Full-text]
729. Prescription of analgesics to patients in opioid maintenance therapy: a pharmacoepidemiological study.
     Drug Alcohol Depend, 116(1): 158-62. [Abstract] [Full-text]
730. Treatment of gastrointestinal angiodysplasia and unmet needs.
     Dig Liver Dis, 43(7): 515-22. [Abstract] [Full-text]
731. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention.
     Drug Alcohol Depend, 116(1): 151-7. [Abstract] [Full-text]
732. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
     Drug Alcohol Depend, 116(1): 52-6. [Abstract] [Full-text]
733. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.
     Drug Alcohol Depend, 116(1): 233-7. [Abstract] [Full-text]
734. Intravesical electromotive botulinum toxin type A administration: part I--Experimental study.
     Urology, 77(6): 1460-4. [Abstract] [Full-text]
735. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.
     BJU Int, 107(12): 1918-22. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.